Patient and transplantation characteristics
. | Donor without KIR ligand incompatibility . | Donor with KIR ligand incompatibility . | P . |
|---|---|---|---|
| N | 103 | 15 | |
| Median patient age, y (range) | 42 (6-62) | 44 (17-57) | .396 |
| Female donor/male recipient (%) | 22 (21) | 3 (20) | |
| CMV status, patient/donor (%) | |||
| +/+ | 29 (28) | 3 (20) | |
| +/− | 27 (26) | 5 (33) | |
| −/+ | 12 (12) | 1 (7) | |
| −/− | 34 (33) | 6 (40) | |
| Diagnosis (%) | |||
| AML | 52 (50) | 7 (46) | |
| CR1/2 | 27 | 3 | .45 |
| Resistant/relapse | 25 | 4 | .85 |
| MDS | 10 (10) | 4 (27) | .08 |
| CML | 41 (40) | 4 (27) | .48 |
| CP 1 | 14 | 4 | .45 |
| CP 2/AP/BC | 14 | 0 | .14 |
| Patient/donor HLA compatibility | |||
| More than 1 allele mismatch (%) | 18 (17) | 4 (27) | |
| Source of stem cells (%) | |||
| BM | 47 (46) | 7 (47) | |
| PBSCs | 56 (54) | 8 (53) | |
| Preparative regimen (%) | |||
| TBI-based | 17 (17) | 1 (7) | .32 |
| Busulfan-based | 83 (81) | 14 (93) | |
| Others | 3 (3) | 0 | |
| CD34+ selection (%) | 21 (20) | 2 (13) | .46 |
| Median CD34+ count, × 106/kg (range) | 4.9 (0.18-26.0) | 3.84 (0.9-10.18) | .84 |
| Graft failure (%) | 10 (10) | 2 (13) | |
| GVHD (%) | |||
| Acute GVHD grades II-IV | 64 (69) | 6 (46) | .28 |
| Chronic GVHD | 37 (45) | 4 (33) | .46 |
. | Donor without KIR ligand incompatibility . | Donor with KIR ligand incompatibility . | P . |
|---|---|---|---|
| N | 103 | 15 | |
| Median patient age, y (range) | 42 (6-62) | 44 (17-57) | .396 |
| Female donor/male recipient (%) | 22 (21) | 3 (20) | |
| CMV status, patient/donor (%) | |||
| +/+ | 29 (28) | 3 (20) | |
| +/− | 27 (26) | 5 (33) | |
| −/+ | 12 (12) | 1 (7) | |
| −/− | 34 (33) | 6 (40) | |
| Diagnosis (%) | |||
| AML | 52 (50) | 7 (46) | |
| CR1/2 | 27 | 3 | .45 |
| Resistant/relapse | 25 | 4 | .85 |
| MDS | 10 (10) | 4 (27) | .08 |
| CML | 41 (40) | 4 (27) | .48 |
| CP 1 | 14 | 4 | .45 |
| CP 2/AP/BC | 14 | 0 | .14 |
| Patient/donor HLA compatibility | |||
| More than 1 allele mismatch (%) | 18 (17) | 4 (27) | |
| Source of stem cells (%) | |||
| BM | 47 (46) | 7 (47) | |
| PBSCs | 56 (54) | 8 (53) | |
| Preparative regimen (%) | |||
| TBI-based | 17 (17) | 1 (7) | .32 |
| Busulfan-based | 83 (81) | 14 (93) | |
| Others | 3 (3) | 0 | |
| CD34+ selection (%) | 21 (20) | 2 (13) | .46 |
| Median CD34+ count, × 106/kg (range) | 4.9 (0.18-26.0) | 3.84 (0.9-10.18) | .84 |
| Graft failure (%) | 10 (10) | 2 (13) | |
| GVHD (%) | |||
| Acute GVHD grades II-IV | 64 (69) | 6 (46) | .28 |
| Chronic GVHD | 37 (45) | 4 (33) | .46 |
CMV indicates cytomegalovirus; CR, complete remission; CP, chronic phase; AP, accelerated phase; BC, blast crisis; BM, bone marrow; PBSCs, peripheral blood stem cells; TBI, total body irradiation; GVHD, graft-versus-host disease.